Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer

Journal of Clinical Oncology

Volumn 21, Issue 8, 2003, Pages 1498-1504

  Hamid, Oday ^a   Varterasian, Mary L ^a   Wadler, Scott ^a   Hecht, J Randolph ^a   Benson III, Al ^a   Galanis, Evanthia ^a   Uprichard, Margaret ^a   Omer, Charles ^a   Bycott, Paul ^a   Hackman, Robert C ^a   Shields, Anthony F ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; NEUTRALIZING ANTIBODY; ONYX 015; VIRUS DNA; ANTINEOPLASTIC AGENT; VIRUS ANTIGEN; VIRUS VACCINE;

ADENOVIRUS; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; FLU LIKE SYNDROME; HUMAN; IMMUNE RESPONSE; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT RESPONSE; VIRUS PARTICLE; VIRUS REPLICATION; VOMITING; ADULT; AGED; AUTOPSY; COLORECTAL TUMOR; DISEASE COURSE; DRUG ADMINISTRATION; FEMALE; IMMUNOLOGY; MALE; MIDDLE AGED; PATHOLOGY; TISSUE DISTRIBUTION; TREATMENT FAILURE;

ADENOVIRIDAE; ADULT; AGED; ANTIGENS, VIRAL; ANTINEOPLASTIC AGENTS; AUTOPSY; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; TISSUE DISTRIBUTION; TREATMENT FAILURE; VIRAL VACCINES;

EID: 0038518576     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.09.114     Document Type: Article

References (23)

1. Cunningham D, Findlay M: The chemotherapy of colon cancer can no longer be ignored. Eur J Cancer 29A:2077-2079, 1993
2. Bischoff JR, Kim DH, Williams A: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274:373-376, 1996
3. Hollstein M, Rice K, Greenblatt MS, et al: Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res 22:3551-3555, 1994
4. Yew PR, Kao CC, Berk AJ: Dissection of functional domains in the adenovirus 2 early 1B55K polypeptide by suppressor-linker insertional mutagenesis. Virology 179:795-805, 1990
5. Lechner MS, Mack DH, Finicle AB, et al: Human papilloma virus E6 proteins bind p53 in vivo and abrogate p53-mediated repression of transcription. EMBO J 11:3045-3052, 1992
6. Gannon JV, Lane DP: P53 and DNA polymerase alpha compete for binding to SV40 T antigen. Nature 329:456-458, 1987
7. Barker DD, Berk AJ: Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology 156:107-121, 1987
8. Hall AR, Dix BR, O'Carroll SJ, et al: p53-dependent cell death/apoptosis is required for a productive adenovirus infection. Nat Med 4:1068-1072, 1998
9. Kim D, Hermiston T, McCormick LF: ONYX-015: Clinical data are encouraging. Nat Med 4:1341-1342, 1998
10. Reid T, Galanis E, Abbruzzese J, et al: Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: A phase I trial. Gene Ther 8:1618-1626, 2001
11. Nemunaitis J, Cunningham C, Buchanan A, et al: Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: Safety, feasibility and biological activity. Gene Ther 8:746-759, 2001
12. Mulvihill S, Warren R, Venook A, et al: Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: A phase I trial. Gene Ther 8:308-315, 2001
13. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989
14. Shields AF, Hackman RC, Fife KH, et al: Adenovirus infections in patients undergoing bone-marrow transplantation. N Engl J Med 312:529-533, 1985
15. Khuri FR, Nemunaitis J, Ganly I, et al: A controlled trial of intratumoral ONYX-015, a selectively replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 6:879-885, 2000
16. Nemunaitis J, Khuri F, Arseneau J: Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol 19:289-298, 2001
17. Vasey P, Shulman L, Campos S, et al: Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (di1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J Clin Oncol 20:1562-1569, 2002
18. Petit T, Davidson K, Cerna C, et al: Efficient induction of apoptosis by ONYX-015 adenovirus in human colon cancer cell lines regardless of p53 status. Anticancer Drugs 13:47-50, 2002
19. Heise C, Sampson-Johannes A, Williams A, et al: ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 3:639-645, 1997
20. Vollmer C, Ribas A, Butterfield L, et al: p53 selective and nonselective replication of an E1B-deleted adenovirus in hepatocellular carcinoma. Cancer Res 59:4369-4374, 1999
21. Chen Y, Yu D, Charlton D, et al: Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: Implications and proposals for human therapy. Hum Gene Ther 11:1553-1567, 2000
22. Cripe TP, Dunphy EJ, Holub AD, et al: Heterogeneous expression of the coxsackievirus-adenovirus receptor that limits adenovirus gene transfer and oncolysis for human rhabdomyosarcoma cells. Cancer Res 61:2953-2960, 2001
23. Bergelson JM, Cunningham JA, Droguett G, et al: Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 275:1320-1323, 1997